Mylan, Teva Lose Actavis Infringement Defense in Valeant Suit
May 2, 2018
Bloomberg Law
On May 1, 2018 a district court ruled in favor of Finnegan client Valeant Pharmaceuticals, ruling that defendants Mylan and Actavis were unable to prove a patent on Valeant's Relistor drug is invalid due to obviousness. The court said, "[t]he bottom line is that Defendants have pointed to no evidence that claim 8 was either an 'identified, predictable solution' or an 'anticipated success.'"